Informace o publikaci
Chronická myeloidná leukémia
| Autoři | |
|---|---|
| Rok publikování | 2011 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Postgraduální medicína |
| Fakulta / Pracoviště MU | |
| Citace | |
| Obor | Onkologie a hematologie |
| Klíčová slova | BCR-ABL; Philadelphia chromosome; imatinib |
| Popis | Chronic myeloid leukemia is a clonal myeloproliferative disorder. It is associated with translocation of chromosones 9 and 22 and so-called Philadelphia chromosome is formed. It is usually diagnosed in its chronic phase but CML has the potential of progression to an agressive form. Imatinib, an inhibitor of tyrosine kinases, has revolutionised the treatment of this disease and is recommended as a standard therapy of its chronic phase. Interferon alpha is an accepted alternative therapy in patients who are intolerant to imatinib. If treatment with standard doses of imatinib fails, it is indicated to increase its doses, to use second generation tyrosine kinase inhibitors or hematopoietic transplantation. |